Cargando…
Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
An emerging paradigm of research has suggested that in the setting of diabetes mellitus (DM) the quality or function of high-density lipoprotein (HDL) may be a determinant of cardiovascular disease risk. Specific structural modifications of HDL protein and lipid components, resulting from oxidative...
Autores principales: | Schwartz, Avery, Blum, Shany, Asleh, Rabea, Pollak, Mordechai, Kalet-Litman, Shiri, Levy, Andrew P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513196/ https://www.ncbi.nlm.nih.gov/pubmed/23226030 |
Ejemplares similares
-
Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype
por: Asleh, Rabea, et al.
Publicado: (2008) -
Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice
por: Asaf, Roy, et al.
Publicado: (2009) -
Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation
por: Asleh, Rabea, et al.
Publicado: (2018) -
In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease
por: Asleh, Rabea, et al.
Publicado: (2005) -
Haptoglobin Genotype Is a Determinant of Hemoglobin Adducts and Vitamin E Content in HDL
por: Goldenstein, Hagit, et al.
Publicado: (2018)